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The ability to reversibly switch between invasive and non-invasive phenotype has 
been considered to be critical for the high malignancy of melanoma. Increasing evidence 
suggests that this ability is determined by the activities of microphthalmia-associated 
transcription factor (MITF) and EMT-related transcription factors (EMT-TFs). GLI1 and 
GLI2, the components of Hedgehog (HH) pathway, are associated with progression and 
invasiveness of melanoma. Although GLI2 is known to suppress MITF expression and to 
promote invasive phenotype of melanoma, the role of GLI1 remains elusive. Here I show 
that inhibition of Shh-pathway by cyclopamine or GLI1 knockdown ( Gli1 KD) decreased 
migration and invasion activity of mouse and human melanoma without affecting MITF 
levels. I observed that Gli1 KD B16F10 melanoma cells exhibited a loss of mesenchymal-
like characteristic as indicated by an increased expression of E-cadherin and a decreased 
expression of mesenchymal markers. To gain insight into the molecular mechanism, I 
analyzed several EMT-TFs that are known to regulate melanoma invasiveness. My 
analysis suggested that the expression of SNAIL1, ZEB1, and TWIST1, but not SNAIL2 
and ZEB2, are directly regulated by GLI1. Collectively my findings suggest a regulatory 
role of GLI1 on a subset of EMT-TFs to promote invasive phenotype of melanoma 




Ab  antibody 
BRAFi  BRAF inhibitor 
BSA  bovine serum albumin 
DAPI   4’,6-diamidino-2-phenylindole 
ChIP  chromatin immunoprecipitation 
DMSO  dimethyl sulfoxide 
dpi  day post-infection 
kb  kilobase 
EGFP  enhanced green fluorescent protein 
EMEM Eagle's Minimum Essential Medium 
EMT  epithelial-to-mesenchymal transition 
EMT-TF EMT-inducing transcription factor 
FBS  fetal bovine serum 
GLI1  glioma-associated oncogene homolog 1 
KD  knockdown 
Luc  luciferase 
MEF  mouse embryonic fibroblast 
MITF  microphthalmia-associated transcription factor 
MTT  Thiazolyl Blue Tetrazolium Bromide 
PATCH Patched 
PBS   phosphate buffered saline  
PCR  polymerase chain reaction 
qPCR  quantitative PCR 
PD-1  programmed death 1 
PFA   paraformaldehyde  
qRT-PCR quantitative reverse-transcription PCR 
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RPMI  Roswell Park Memorial Institute 
shGli1  shRNA targeting Gli1 
Shh  sonic hedgehog 
shLuc  shRNA targeting Luc 
shRNA short hairpin RNA 
SMO  Smoothened 
TGF  transforming growth factor 






Melanoma incidence is increasing over past 50 years. It represents a small 
percentage of skin cancers, but is the major cause of mortality from these cancers.(1,2) The 
primary source of melanoma is melanocytes (pigment cells) that underwent a mutation 
that lead to the constitutive activation of MAPK signaling pathway. Approximately 50% 
of melanomas harbor the activating BRAFV600E mutation.(3) Current therapies for 
metastatic melanoma provides only transient response and modest disease-free survival.  
Although small molecule inhibitors targeting BRAF and MEK, a downstream effector of 
BRAF, are effective in BRAF-mutated melanoma, virtually all of the tumors develop 
resistance to the drugs, usually within a few months.(4-10) On the other hand, immune 
checkpoint inhibitors, such as an anti-programmed death 1 (PD-1) antibody, provide 
durable responses in patients with metastatic melanoma independent of the BRAF 
mutational status; however, a significant proportion of the patients either do not respond 
or develop resistance to the PD-1 immunotherapy.(11-15) 
Tumor heterogeneity poses a major challenge for the effective treatment of cancer. 
Accumulating evidence indicates that the heterogeneity in melanoma can be driven 
through phenotypic plasticity.(16-18) That is, the aggressiveness of melanoma appears to 
be due to the cancer cells’ ability to reversibly switch between different phenotypes with 
non-invasive and invasive potentials. Microphthalmia-associated transcription factor 
(MITF) plays an essential role in determining the melanocyte lineage and has been 
proposed to act as a rheostat for the cellular heterogeneity in melanoma.(17,19,20) In the 
rheostat model, low levels of MITF generate invasive, stem-like cells, whereas high MITF 
levels stimulate proliferation and inhibit invasion.  
Acquisition of invasive phenotype is an important step for metastasis of melanoma 
which involves downregulation of melanocyte differentiation program accompanied by 
decreased expression of E-cadherin, increase expression of mesenchymal markers, and 
enhanced invasion. This process resembles the epithelial-mesenchymal transition (EMT) 
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in carcinoma.  Epithelial-to-mesenchymal transition (EMT) is a dynamic and reversible 
phenotypic switching process from polarized epithelial cells to motile mesenchymal cells; 
this process is essential for normal development and is widely thought to be a critical 
switch for tumor-cell invasiveness.(21-23) EMT is driven by an interconnected signaling 
network of EMT-inducing transcription factors (EMT-TFs), including SNAIL, TWIST, 
and ZEB. Recent studies have shown that some EMT-TFs play important roles in 
malignant melanoma, but their regulation and function are different from those in 
epithelial cancers.(24,25) These studies also suggest that the EMT-TFs SNAIL2 and ZEB2 
act as tumor-suppressor proteins by activating an MTIF-dependent melanocyte 
differentiation program. 
Hedgehog-Gli (HH-Gli) pathway is an intercellular signaling pathway playing a role 
in determining proper embryonic patterning and cell fate during development. HH-Gli 
pathway plays important roles in various cancers. Sonic hedgehog (Shh) signaling has 
critical roles in embryonic patterning, and aberrant Shh-signaling activation is implicated 
in various cancer types, including skin cancer.(26-29) The Shh signal is transduced by a 
receptor complex composed of two proteins, Patched (PTCH) and Smoothened (SMO). 
The binding of Shh to PTCH relieves PTCH’s repression of SMO. HH-Gli signaling is 
active in hair follicles and required for normal proliferation of melanocyte. HH-Gli 
pathway also regulates proliferation, survival and self-renewal of melanoma. The 
transcription factor glioma-associated oncogene homolog 1 (GLI1) acts as a terminal, 
positive effector of Shh signaling. GLI1 is known to induce the expression of EMT-TFs 
to promote EMT and invasion in various cancers and has been proposed as an attractive 
target for cancer. GLI1’s expression and activity are also regulated through a non-
canonical Shh pathway, such as those involving hypoxia or transforming growth factor 
(TGF)-β.(30-32) GLI1 has been suggested to be involved in melanoma progression, 
although its precise role and the mechanism underlying invasion remain unclear. 
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In the present study, I analyzed the role of HH-Gli pathway in the regulation of 
invasive phenotype with respect to EMT and MITF expression levels. Unexpectedly I 
found that modulation of MITF levels is not required for HH-Gli-induced EMT and 
invasion. My results showed HH-Gli pathway activation is capable of inducing invasion 
in MITF-overexpressing cells. I propose HH-Gli pathway may serves as a signaling cue 
that regulate EMT-TFs expression to drive invasive phenotype independent of the MITF. 





2. Materials and methods 
Cell Culture 
B16F10 murine melanoma cells were obtained from Riken BioResource (Tokyo, Japan), 
and MeWo and G361 human melanoma cells from JCRB Cell Bank (Osaka, Japan). 
B16F10 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium 
(Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS), 
and MeWo and G361 cells in Eagle's Minimum Essential Medium (EMEM) with non-
essential amino acids (Wako, Tokyo, Japan) and 10% FBS. To prepare conditioned 
medium, NIH3T3 cells, a kind gift from Dr. Chiaki Takahashi (Kanazawa University, 
Kanazawa, Japan), were cultured in RPMI 1640 (Nissui Pharmaceutical) supplemented 
with 10% FBS. Mouse embryonic fibroblasts (MEFs) and HEK293T cells were cultured 
as described previously (33). In some experiments, cyclopamine (LKT Labs, St. Paul, MN, 
USA) and forskolin (Wako) were dissolved in dimethyl sulfoxide (DMSO) and added to 
the culture medium (see Figure 3.1 and Figure 3.2). 
 
Plasmids, viral vector preparation, and viral infection 
The pLVTH lentivirus plasmid vectors for short hairpin RNAs (shRNAs) were 
constructed as previously described.(34) In pLVTH, enhanced green fluorescent protein 
(EGFP) is encoded as a marker. Previously reported target sequences, which are listed in 
Table 1, were used to express shRNAs against mouse Gli1, human Gli1, and firefly 
Luciferase (Luc). Lentiviral vectors were produced as previously described.(34) B16F10, 
MeWo, and G361 cells were infected with the lentiviruses, and were analyzed at 7 days 
post-infection (dpi). The mammalian expression plasmid pCL20c-CMV-EGFP was 
described previously(34). To generate pCL20c-CMV-HA-GLI1, the JSAP1-coding 
sequence in pCL20c-CMV-HA-JSAP1(34) was replaced with the mouse GLI1-coding 
sequence. The potential promoter regions of Snail1, Zeb1, and Twist1 were obtained by 
polymerase chain reaction (PCR) using B16F10 genomic DNA as templates. The PCR 
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products were subcloned into a promoter-less pGL3 vector (Promega, Madison, WI, 
USA), and used for the Luc assays in Figure 5. All PCR products were verified by 
sequencing. 
 
Table 1. List of oligonucleotides for the shRNA constructs used in this study. The 
underlined letters represent mouse Gli1, human Gli1, or firefly Luc sequences. 
 
Gene Oligonucleotide Reference 












































Western blot analysis 
Total cell lysates were prepared and analyzed by Western blotting as previously 
described,(34) using rabbit anti-GLI1 H300 (sc-20687), rabbit anti-E-cadherin H108 (sc-
7870) (each diluted to 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit 
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anti-MITF N2C1 (1:1000; GTX113776; GeneTex, Irvine, CA, USA), and mouse anti-α-
tubulin (1:3000; #T5168; Sigma-Aldrich, St. Louis, MO, USA) antibodies (Abs). 
 
Quantitative reverse-transcription PCR (qRT-PCR) 
Total RNA was prepared and qRT-PCR was performed as previously described.(35) 
Primers used for qRT-PCR are listed in table 2. 
 
Table 2. List of qRT-PCR primers used in this study. 
F: Forward primer. R: Reverse primer 
 
Gene Primer Reference 
mouse Cdh1 F: 5’-ATTGCAAGTTCCTGCCATCCTC-3’ 
R: 5’-CACATTGTCCCGGGTATCATCA-3’ 
(65) 
mouse Cdh2 F: 5’-AGTTTCTGCACCAGGTTTGG-3’ 
R: 5’-CATACGTCCCAGGCTTTGA-3’ 
(66) 
mouse Fn1 F: 5’-GCTCAGCAAATCGTGCAGC-3’ 
R: 5’-CTAGGTAGGTCCGTTCCCACT-3’ 
(67) 
mouse Gapdh F: 5’-AAATGGTGAAGGTCGGTGTG-3’ 
R: 5’-TGAAGGGGTCGTTGATGG-3’ 
(68) 
mouse Mitf F: 5’-GCCTGAAACCTTGCTATGCT-3’ 
R: 5’-TACCTGGTGCCTCTGAGCTT-3’ 
(69) 
mouse Snail1 F: 5’-GTGGAAAGGCCTTCTCTAGGC-3’ 
R: 5’-GGTTGGAGCGGTCAGCAAAA-3’ 
(70) 
mouse Snail2 F: 5’-TGGTCAAGAAACATTTCAACGCC-3’ 
R: 5’-GGTGAGGATCTCTGGTTTTGGTA-3’ 
(72) 





mouse Tyr F: 5’-CTCTGGGCTTAGCAGTAGGC-3’ 
R: 5’-GCAAGCTGTGGTAGTCGTCT-3’ 
(67) 
mouse Vim F: 5’-GGACGTTTCCAAGCCTGACCTC-3’ 
R: 5’-CCGGTACTCGTTTGACTCCTGC-3’ 
(73) 
mouse Zeb1 F: 5’-GATCCAGCCAAACGGAAACC-3’ 
R: 5’-TGGCGTGGAGTCAGAGTCAT-3’ 
(70) 
mouse Zeb2 F: 5’-GGGACAGATCAGCACCAAAT-3’ 
R: 5’-GACCCAGAATGAGAGAAGCG-3’ 
(73) 
human CDH2 F: 5’-TGCGGTACAGTGTAACTGGG-3’ 
R: 5’-GAAACCGGGCTATCTGCTCG-3’ 
(67) 
human FN1 F: 5’-AGGAAGCCGAGGTTTTAACTG-3’ 
R: 5’-AGGACGCTCATAAGTGTCACC-3’ 
(67) 
human GAPDH F: 5’-ACCCAGAAGACTGTGGATGG-3’ 
R: 5’-TCTAGACGGCAGGTCAGGTC-3’ 
(70) 
human TYR F: 5’-CTGGAAGGATTTGCTAGTCCAC-3’ 
R: 5’-CCTGTACCTGGGACATTGTTC-3’ 
(74) 




Phalloidin staining and immunocytochemistry 
B16F10 cells plated on coverslips coated with poly-L-lysine (Sigma-Aldrich) were fixed 
with 4% paraformaldehyde (PFA), washed with 0.1% Triton X-100 in phosphate buffered 
saline (PBS), and stained with rhodamine-phalloidin (1:500; Thermo Fisher Scientific, 
Waltham, MA, USA) and 4’,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) to 
visualize F-actin and nuclei, respectively. Fluorescent images were captured with a 
fluorescence microscope (BX50, Olympus, Tokyo, Japan). Immunocytochemistry was 
performed by standard protocols as previously described,(34) using the rabbit anti-E-
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cadherin H108 (1:200; Santa Cruz Biotechnology) Ab. The secondary Ab was goat Alexa 
fluor 568-conjugated anti-rabbit IgG Ab (1:1000; Thermo Fisher Scientific). Nuclei were 
stained with DAPI (Sigma-Aldrich). Fluorescent images were captured using a confocal 
laser scanning microscope (LSM510 META, Carl Zeiss, Oberkochen, Germany) with a 
20x or 40x objective lens. In some experiments (Figure 3.9d), twelve Z-stack images at 
1.2-μm intervals were acquired using the confocal microscope with a 40x objective lens. 
 
Luc assay 
To measure the GLI-mediated transcriptional repression in response to cyclopamine, 
B16F10 cells were plated in 12-well plates at 8 x 104 cells per well, and were 
cotransfected with 950 ng of the Luc reporter vector (8xGLI-BS-Luc or 8xmGli-BS-Luc, 
kind gifts from Dr. Hiroshi Sasaki, Kumamoto University, Kumamoto, Japan)(36) and 50 
ng of the Renilla Luc control vector (pRL-TK-Luc, Promega) using Lipofectamine LTX 
with Plus reagent (Thermo Fisher Scientific). Six hours after transfection, the medium 
was changed, and the cells were treated with either vehicle (DMSO) or cyclopamine for 
24 hours. The cells were then lysed, and the Luc activity was measured as previously 
described.(34) To examine the effect of GLI1 overexpression on the potential promoters 
of Snail1, Zeb1, and Twist1, 350 ng of the Luc reporter vector containing the potential 
promoter region, 140 ng of either pCL20c-CMV-EGFP or pCL20c-CMV-HA-GLI1, and 
10 ng of pRL-TK-Luc were cotransfected into HEK293T cells plated in 12-well plates at 
2 x 105 cells per well. Thirty-six hours after transfection, the cells were lysed, and 
subjected to Luc assays as described previously(34). 
 
Matrigel invasion assay 
The cell invasion assay was carried out using Transwell chambers with inserts of an 8-
μm pore size (Corning, Corning, NY, USA). The upper chamber was pre-coated with 
Matrigel (300 μg/ml, 100 μl per well for B16F10 cells; 200 μg/ml, 100 μl per well for 
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MeWo cells, BD Biosciences, San Jose, CA, USA). NIH3T3-conditioned medium 
containing 10% FBS (for B16F10 cells) or EMEM complete growth medium 
supplemented with 10% FBS (for MeWo and G361 cells) was added to the lower chamber, 
which was pre-coated with 50 μl of fibronectin (50 μg/ml) (Thermo Fisher Scientific), 
and then 1x105 cells were seeded on the upper chamber in serum-free medium containing 
0.1% bovine serum albumin (BSA). In some experiments (Figure 3.1), cyclopamine was 
added to both the upper and lower chambers. At 24 hours (for B16F10 cells) or 30 hours 
(for MeWo and G361 cells) after seeding, the cells were fixed in 4% PFA and stained 
with 0.1% crystal violet. Cells remaining on the upper side of the inserts were scraped 
with cotton swabs, and cells on the lower side were counted. 
 
Cell migration assay 
To measure the cell migration activity, wound-healing (for B16F10 cells) and Transwell 
chamber (for MeWo and G361 cells) assays were performed. B16F10 cells were replated 
at a saturation density (2 x 105 cells per well of a 12-well plate) in RPMI 1640 
supplemented with 1% FBS, and incubated for 6 hours. The plates were then scratched 
manually with a sterile pipette tip. After being washed with RPMI 1640, the wounded 
regions were allowed to heal for 12 hours in RPMI 1640 medium supplemented with 1% 
FBS. The cell movements were monitored using a cultured cell monitoring system (CCM-
1.4XYZ/CO2, Astec, Fukuoka, Japan). Video images were collected at 15-minute 
intervals for 12 hours. Transwell chamber migration assays were carried out as described 
above (Matrigel invasion assay) without pre-coating the upper chamber. 
 
Thiazolyl Blue Tetrazolium Bromide (MTT) assay 
The MTT assay was used to examine cell viability. B16F10, MeWo, or G361 cells were 
seeded in 24-well plates (8 x 104 cells per well), and incubated overnight. The medium 
was then changed to serum-free medium containing 0.1% BSA, and the cells were 
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incubated for 24 hours to mimic the Matrigel invasion assay described above. In some 
experiments (Figure 3.2), cyclopamine was added to the culture medium. The cells were 
washed with PBS and incubated with MTT solution (0.5 mg/ml, Sigma) for 1 hour. The 
resulting insoluble formazan was dissolved in 0.04 N HCl in isopropanol, and the 
absorbance at 595 nm was measured. 
 
Chromatin immunoprecipitation (ChIP) assays 
ChIP assays were performed essentially as described previously(37). B16F10 cells were 
fixed in formaldehyde, then lysed by sonication using a Bioruptor sonicator (CosmoBio, 
Tokyo, Japan). The lysates were immunoprecipitated with the rabbit anti-GLI1 H300 Ab 
(sc-20687; Santa Cruz Biotechnology) or control rabbit IgG (011-000-003; Jackson 
ImmunoResearch Laboratory, West Grove, PA, USA), and the precipitated DNA was 
subjected to quantitative PCR (qPCR). Primers used for the qPCR are listed in Table 3. 
 
Table 3. List of qPCR primers used in this study. 
F: Forward primer. R: Reverse primer 
 
PCR target site Primer PCR length (bp) 
Snail S1 F: 5’-CCAGTGCTGGGAGTCTGATT-3’ 
R: 5’-CTGAAAATCGTGTTGGAACG-3’ 
190 
Snail S2 F: 5’-CACCTGCCCTTATTGGTGTT-3’ 
R: 5’-TTGAGAGCAGGTTCCAGGAT-3’ 
182 
Zeb1 Z1 F: 5’-CTCAGGCTCCTGACTTTTCG-3’ 
R: 5’-AAGAAATTCCGCTCACAGGA-3’ 
174 
Zeb1 Z2 F: 5’-CAGCAGAACGAGCCAGGTAG-3’ 
R: 5’-TTCCTAGGCCAGGTTGAGC-3’ 
179 









All experimental procedures involving mice were approved by the Institutional Animal 
Care and Use Committee of Kanazawa University. To evaluate the cells’ metastatic 
ability, in vivo metastasis assays were performed in mice. B16F10 cells suspended in 200 
μl of PBS containing 5% FBS were injected into the tail vein of 8-week-old male 
C57BL/6 mice (Sankyo Labo Service, Tokyo, Japan). The mice were sacrificed 14 days 
after the inoculation, and the lungs were fixed in 10% formaldehyde. The metastatic foci 




Significance was determined using a two-tailed unpaired Student’s t-test. Values of P < 





Blockade of Shh signaling inhibits the invasion ability of melanoma cells without 
affecting their MITF expression and activity 
To examine the role of Shh signaling in maintaining the invasive phenotype of 
melanoma cells, I blocked the Shh-GLI signaling pathway using cyclopamine, an 
inhibitor of SMO. I used a highly metastatic murine melanoma cell line, B16F10 cells, 
which is widely used as a model system to study melanoma biology. B16F10 cells were 
treated with cyclopamine at relatively low concentrations, 2.5 µM and 5 µM. The 
inhibition of Shh-GLI signaling pathway was confirm as shown by decreased levels of 
GLI1 protein and of GLI-mediated transcriptional activity, in a dose-dependent manner 
(Figure 3.1a,b). In addition, I also examined the expression of GLI2 and GLI3, which 
mainly function as a transcriptional activator and repressor, respectively. GLI2 protein 
levels was decreased by cyclopamine, but to a lesser degree than GLI1 (Figure 3.1b). The 
processed, repressive form of GLI3 (GLI3-R) was slightly increased, and full-length 
GLI3 (GLI3-FL) was decreased, in cyclopamine-treated B16F10 cells in a dose-
dependent manner (Figure 3.1c). As shown in Figure 3.1d,e, blocking Shh signaling with 
cyclopamine caused a dose-dependent decrease in invasion activity, in which a 
statistically significant difference was observed between cyclopamine-untreated and -
treated B16F10 cells at 5 µM, but not 2.5 µM. There was no significant effect of 
cyclopamine at either concentration on cell viability, under the conditions used for the 
invasion assay (Figure 3.2). 
The invasive phenotype of melanoma cells is often characterized by low levels of 
MITF. Therefore, I examined the expression levels of MITF in cyclopamine-treated 
B16F10 cells at 2.5 µM and 5 µM. The protein and mRNA levels of MITF were 
comparable among these cells (Figure 3.1b,f). There were also no significant differences 
in the mRNA levels Tyrosinase (Tyr), a MITF-target gene, in these cells (Figure 3.1g). 




Figure 3.1. Blockade of Shh signaling inhibits the invasion activity of melanoma cells. (a) 
B16F10 cells were cotransfected with a firefly Luc reporter plasmid containing GLI-binding 
sites (8xGli-BS-Luc) or mutated sites (8xmGli-BS-Luc) together with a Renilla Luc reporter 
plasmid, and were assayed for Luc activity, as described in Materials and Methods. (b,c) 
B16F10 cells were treated with cyclopamine for 48 hours at the indicated concentrations, and 
were then subjected to Western blotting using anti-GLI1, -GLI2, -MITF (b), and -GLI3 (c) 
Abs. Lane 1, cell lysate prepared from MEFs. α-tubulin was used as a loading control. (d) 
B16F10 cells were pre-treated with cyclopamine for 24 hours at the indicated concentrations, 
and were then subjected to a Matrigel invasion assay. Representative images captured using a 
microscope (BX50, Olympus) are shown. (e) Quantification of the results in (d). The average 
numbers of invading cells from five randomly chosen fields acquired using a 20x objective 
lens are shown. (f,g) B16F10 cells were untreated or treated with cyclopamine for 48 hours at 
the indicated concentrations, and the relative mRNA levels of Mitf (e) and Tyr (f) were then 
measured by qRT-PCR. The expression levels were normalized to Gapdh. Quantitative data 
are expressed as the mean ± S.E.M of three independent experiments. *P < 0.05; **P < 0.01; 
***P < 0.001; n.s., not significant. Cyc, cyclopamine; NT, untreated. 
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in the B16F10 cells, I stimulated the cells with forskolin, a cAMP-elevating reagent 
known to induce Mitf expression. As expected, the protein levels of MITF and mRNA 
Tyr were increased, in the forskolin-treated B16F10 cells (Figure 3.3). Taken together, 
these results indicated that blocking the Shh signaling by cyclopamine at low 
concentration inhibits the invasion ability of B16F10 melanoma cells without affecting 


















Gli1 KD inhibits the invasion ability and migration of melanoma cells, 
independently of the regulation of MITF expression and activity 
I next asked whether GLI1 is important for the invasive phenotype of melanoma 
cells. I knockdown Gli1 in B16F10 cells using two Gli1-targeting lentiviral shRNAs  
Figure 3.2. Blockade of Shh signaling shows no 
significant effect on cell viability. B16F10 cells untreated 
or treated with cyclopamine at the indicated 
concentrations were cultured under the conditions used for 
the invasion assay (see Materials and Methods, Matrigel 
invasion assay), and were then analyzed by MTT assay. “0 
μM cyclopamine” denotes vehicle treatment. The 
activities are shown as a percentage of the MTT activity 
of vehicle-treated control cells and are expressed as the 
mean ± S.E.M of three independent experiments. Cyc, 
cyclopamine; NT, untreated. n.s., not significant. 
Figure 3.3.  Forskolin induces the expression of MITF protein and its target gene Tyr. B16F10 
cells were untreated or treated with either vehicle (DMSO) or forskolin (20 μM) for the 
indicated time (a) or for 24 hours (b), and the cells were then analzyed by Western blotting 
using an anti-MITF Ab (a) or by qRT-PCR with Tyr-specific primers (b). Anti-α-tubulin was 
used as a loading control in the Western blot. The relative mRNA levels of Tyr were 
normalized to Gapdh and are expressed as the mean ± S.E.M of three independent 





Figure 3.4.  Gli1 KD inhibits the invasion and migration abilities of melanoma cells. (a) 
B16F10 cells were infected with lentiviral shLuc, shGli1-1, or shGli1-2 (termed 
B16F10_shLuc, B16F10_shGli1-1, and B16F10_shGli1-2 cells, respectively), and the protein 
levels of GLI1 and MITF were examined by Western blotting using anti-GLI1 and -MITF 
Abs. α-tubulin was used as a loading control. (b) Matrigel invasion assays were performed as 
in Figure 3.1b, using B16F10_shLuc, B16F10_shGli1-1, and B16F10_shGli1-2 cells. 
Representative images of invading cells are shown. (c) Quantification of the results in (b), 
performed as described in Figure 3.1e. (d) B16F10_shLuc, B16F10_shGli1-1, and 
B16F10_shGli1-2 cells were analyzed by in vitro wound-healing assays. Phase-contrast time-
lapse images at 0, 3, 6, and 9 hours are shown. Curved red lines indicate the boundary between 
the unscratched and scratched areas. (e) Quantification of wound size using ImageJ software 
(NIH). (f,g) Relative mRNA levels of Mitf (e) and Tyr (f) in B16F10_shLuc, B16F10_shGli1-
1, and B16F10_shGli1-2 cells were measured by qRT-PCR. The expression levels were 
normalized to Gapdh. Quantitative data are expressed as the mean ± S.E.M of three 




(shGli1-1 and shGli1-2) (Figure 3.4a), and then examined the invasion ability and 
migration of the Gli1-knockdown (Gli1 KD) cells. The invasion ability of the KD cells 
was substantially reduced compared to that of control B16F10 cells expressing a Luc-
targeting lentiviral shRNA (shLuc) (Figure 3.4b,c). The cell migration activity was also 
inhibited by knocking down Gli1 (Figure 3.4d,e). No significant differences in viability 
were detected between the shLuc- and shGli1-expressing B16F10 cells under the culture 
conditions used for the invasion assay (Figure 3.5a). Furthermore, exogenous expression 
of GLI1 in B16F10 cells significantly increased the invasion activity (Figure 3.6). Then I 
analyzed the expression levels of MITF (protein and mRNA) and its target gene Tyr in 
the Gli1 KD B16F10 cells, and found that the MITF and Tyr levels were unchanged 
(Figure 3.4a,f,g), as seen in the cyclopamine-treated B16F10 cells. I also observed similar 
effects on the cell migration and invasion abilities and the MITF expression and activity 
in GLI1 KD MeWo (wild-type BRAF/NRAS) and G361 (BRAFV600E) cells, metastatic 
human melanoma cell lines (Figure 3.7). Taken together, these results strongly suggested 
that GLI1 plays a crucial role in maintaining the invasive phenotype of melanoma cells, 
independently of the regulation of MITF expression and activity. 











Figure 3.5.  Gli1 KD shows no significant effects on melanoma cell viability. B16F10_shLuc 
and B16F10_shGli1 (a), MeWo_shLuc and MeWo_shGli1 (b), and G361_shLuc and 
G361_shGli1 (c) cells were cultured under the conditions used for the invasion assay as in 
Figure 3.2, and were analyzed by MTT assay. The activities are shown as a percentage of the 
MTT activity of shLuc-expressing control cells and are expressed as the mean ± S.E.M of 























Gli1 KD prevents the lung metastasis ability of B16F10 cells 
The decreased invasion and migration after Gli1 KD prompted us to examine the 
metastatic ability of the KD cells in vivo. I performed an experimental in vivo metastasis 
assay, in which B16F10 cells expressing shLuc (control) or shGli1 were injected into the 
mouse tail vein, and lung metastasis was evaluated. There were many fewer metastatic 
nodules in the lungs of mice injected with shGli1-expressing cells than in the lungs of 
control B16F10-injected mice (Figure 3.8), indicating that Gli1 KD decreases the lung 
metastasis ability of B16F10 cells. 
Figure 3.6.  GLI1 overexpression of GLI1 enhances the invasion activity of B16F10 cells. 
(a,b) B16F10 cells were infected with a lentiviral vector (pCL20c-CMV(34)) expressing EGFP 
(control) or C-terminally HA-tagged GLI1 (GLI1-HA), and subjected to staining with DAPI 
and an anti-HA Ab (a) and to Westen blotting with anti-HA and anti-GLI1 Abs (b), as 
indicated. (c) Matrigel invasion assays using the infected cells were performed as described 
in Materials and Methods, except that half the number of cells (i.e., 5 x 104) was used. 
Representative images of invading cells are shown. (d) Quantification of the results in (c). The 




























Gli1 KD induces a reversal of the mesenchymal-like phenotype 
Gli1 activity has been associated with EMT in various cancer. I question whether 
the decrease invasion and migration is also associated with this function in melanoma. In 
addition, I noticed that the Gli1 KD B16F10 cells tended to associate with each other and  
Figure 3.7.  Gli1 KD induces a reversal of the mesenchymal-like phenotype in MeWo and 
G361 cells. (a) The protein levels of GLI1 and MITF in MeWo_shLuc, MeWo_shGli1, 
G361_shLuc, and G361_shGli1 cells were examined by Western blotting, using anti-GLI1 
and -MITF Abs. α-tubulin was used as a loading control. (b) Relative mRNA levels of TYR in 
MeWo_shLuc, MeWo_shGli1, G361_shLuc, and G361_shGli1 cells were measured by qRT-
PCR. The expression levels were normalized to GAPDH. Quantitative data are expressed as 
the mean ± S.E.M of three independent experiments. (c) Transwell chamber migration assays 
were performed using MeWo_shLuc, MeWo_shGli1, G361_shLuc, and G361_shGli1 cells. 
(d) Quantification of the results in (c). The average numbers of migrating cells are shown. (e) 
Matrigel invasion assays were performed as described in the legend for Figure 3.1b, using 
MeWo_shLuc, MeWo_shGli1, G361_shLuc, and G361_shGli1 cells. (f) Quantification of the 
results in (e). The average numbers of invading cells as in Figure 3.1c are shown. *P < 0.05; 







Figure 3.8. Gli1 KD decreases the 
lung metastasis ability of B16F10 
cells. (a) Representative images of 
the lungs of mice injected with 
B16F10_shLuc or B16F10_shGli 
cells. (b) Each open circle denotes 
the number of nodules representing 
the pulmonary metastasis ability of 
B16F10_shLucand 16F10_shGli1 
cells in mice treated as in (a). Data 
are the means ± S.E.M (n = 15 mice 
per group). Scale bar, 0.5 cm. 
Figure 3.9. Gli1 KD induces reversal of the mesenchymal-like phenotype. (a) B16F10_shLuc 
and B16F10_shGli1 cells, which express EGFP, were double stained with rhodamine-
phalloidin and DAPI. Lower panels show higher-magnification images of the boxed areas in 
the upper panels. (b) Relative mRNA levels of E-cadherin (Cdh1) in the B16F10_shLuc and 
B16F10_shGli1 cells were measured by qRT-PCR. The expression levels were normalized to 
Gapdh and are expressed as the mean ± S.E.M of three independent experiments. (c) The 
protein levels of E-cadherin in B16F10_shLuc and B16F10_shGli1 cells were examined by 
Western blotting using an anti-E-cadherin Ab. α-tubulin was used as a loading control. (d) 
B16F10_shLuc and B16F10_shGli1 cells were double stained with DAPI and an anti-E-
cadherin Ab. Lower panels show higher-magnification Z-stack images of the boxed areas in 
the upper panels. Z-stack images were acquired using a confocal microscope as described in 
Materials and Methods. (e) Relative mRNA levels of N-cadherin (Cdh2), vimentin (Vim), and 
fibronectin (Fn1) in B16F10_shLuc and B16F10_shGli1 cells were measured by qRT-PCR as 




changed morphologically. Further examination by phalloidin staining showed that stress 
fiber formation was severely inhibited in the Gli1 KD cells (Figure 3.9a). Consistent with 
the changes in morphology and cytoskeletal structures, the expression levels of E-
cadherin (protein and mRNA) were substantially increased, with the E-cadherin protein 
being predominantly localized to areas of cell-cell contact, in the Gli1 KD cells (Figure 
3.9b-d). Furthermore, the mRNA expression levels of mesenchymal markers, such as N-
cadherin and vimentin were significantly decreased in the Gli1 KD cells compared to the 
shLuc-expressing control cells (Figure 3.9e). Similar expression profiles of E-cadherin 
and mesenchymal markers were obtained using MeWo and G361 cells (Figure 3.10), 
although there were no increased cell-cell adhesion in both cell lines as observed in 
B16F10. These results may indicate that GLI1 regulates a subset of EMT-TFs to prevent 
the reverse transition from a mesenchymal-like to an epithelial-like phenotype. 
 
GLI1 transcriptionally regulates the expression of Snail1, Zeb1, and Twist1 
To gain insight into the molecular mechanism, I investigated whether GLI1 
modulates the expression of key EMT-TFs, including SNAIL and ZEB family members. 
As shown in Figure3-11a, the mRNA levels of Snail1, Zeb1, and Twist1 were 
significantly decreased in the Gli1 KD B16F10 cells compared to the control B16F10 
cells, whereas no significant differences in the Snail2 or Zeb2 mRNA levels were 
observed between the Gli1 KD and control cells. Using the MatInspector software(40), I 
identified several putative GLI-binding sites within the one-kilobase (1-kb) upstream 
region of the transcriptional start sites of Snail1, Zeb1, and Twist1 (termed S1 and S2 for 
Snail1; Z1, Z2, and Z3 for Zeb1; and T1, T2, and T3 for Twist1; see Figure 3.11b). I then 
conducted ChIP assays with an anti-GLI1 Ab in B16F10 cells. The precipitated DNAs 
were analyzed by qPCR using primers specific for the GLI1-binding sites. However, 
because the regions around Z3 and T3, which are close to transcriptional start sites, are 




Figure 3.11. GLI1 transcriptionally regulates the expression of Snail1, Zeb1, and Twist1. (a) 
Expression of EMT-TFs in Gli1 KD B16F10 cells. Relative mRNA levels of Snail1, Snail2, 
Zeb1, Zeb2, and Twist1 in B16F10_shLuc and B16F10_shGli1 cells were measured by qRT-
PCR. The expression levels were normalized to Gapdh and are expressed as the mean ± S.E.M 
of three independent experiments. (b) Scheme of the potential promoter regions of Snail1, 
Zeb1, and Twist1, and the Luc reporter. Numbers indicate the position relative to the 
transcriptional start sites (+1). Closed vertical boxes represent putative GLI-binding sites. 
Core sequences of the GLI-binding motif are shown by uppercase letters, in which the 
underlined nucleotides differ from the consensus sequences. Open and closed arrowheads 
indicate qPCR primers. (c-h) ChIP and qPCR (c,e,g), and Luc (d,f,h) assays were performed 


















experiments for them. The ChIP results revealed that GLI1 bound significantly to S1, Z1, 
and T1, but not to S2, Z2, or T2 (Figure 3.11c,e,g and Figure 3.12b). I then examined the 
effect of GLI1 overexpression on the potential promoters of Snail1, Zeb1, and Twist1 
using reporter assays, and found that GLI1 overexpression substantially enhanced the 
promoter activities of the 1-kb regions. The activities were not significantly increased 
when the regions’ corresponding deletion derivatives were used (Figure 3.11d,f,h). 
Collectively, these results strongly suggest that GLI1 binds directly to the promoters of 
Snail1, Zeb1, and Twist1, and regulates their expression. In addition, I found a significant 
co-occurrence between Gli1 and Zeb1 (P = 0.002) and between Gli1 and Sail1 (P = 0.004) 
by analyzing the TCGA cutaneous melanoma dataset (287 samples with RNA sequencing 
expression data) through the cBioPortal for cancer genomic data using mutual exclusivity 
analysis (41,42). 
 
Figure 3.12. Primers used in ChIP assays, and agarose gels of PCR products. (a) Schematic 
representation of the regions surrounding putative GLI-binding sites in the promoter regions 
of Snail1, Zeb1, and Twist1. Closed vertical boxes indicate putative GLI-binding sites. Open 
and closed arrowheads represent primers (see Table S3) used for the ChIP and PCR analyses 
shown in Figure 5b. Numbers indicate positions relative to the transcriptional start sites (+1) 
of Snail1, Zeb1, and Twist1. (b) Agarose gels of PCR products. Chromatin was prepared from 
fixed and sonicated B16F10 cells expressing lentiviral shLuc, and subjected to PCR. Input 
DNA (lanes 1 and 4) and ChIP DNA with IgG (lanes 2 and 5) and anti-GLI1 Ab (lanes 3 and 
6) were amplified by PCR (30 cycles) using primer sets for the Snail1 S1 (lanes 1-3) and S2 
(lanes 4-6) sites, Zeb1 Z1 (lanes 1-3) and Z2 (lanes 4-6) sites, and Twist1 T1 (lanes 1-3) and 





The expression level of MITF is thought to be the key factor in determining the 
proliferative or invasive state of melanoma according to MITF-dependent phenotype 
switching model. MITF is a key molecule that regulates heterogeneity in melanoma, and 
the MITF rheostat model has become widely accepted in melanoma biology. In the 
present study, I demonstrated for the first time that the transcription factor GLI1 plays an 
important role in maintaining the invasive phenotype of melanoma cells without affecting 
the MITF expression and activity. I also showed that GLI1 prevents the reversal of the 
mesenchymal-like phenotype of melanoma cells, most likely by modulating a subset of 
EMT-TFs. These findings provide new insight into how a high degree of heterogeneity 
and plasticity is achieved and regulated in melanoma. 
Microenvironmental factors, such as hypoxia or TGF-β, are known to influence 
both MITF expression and the phenotype switching of melanoma cells.(17,20,43-46) In 
addition, Pierrat et al.(43) reported that Mitf is down-regulated by GLI2 and TGF-β to 
antagonize the MITF activity. Furthermore, Faião-Flores et al.(46) recently showed that 
the GLI1 and GLI2 expressions increase upon the acquisition of BRAF inhibitor (BRAFi) 
resistance in melanoma cell lines and patient melanoma samples, where again the inverse 
correlation between GLI2 and MITF expression is observed. On the other hand, in this 
study I found that GLI1 exerts its function with little or no effect on the MITF expression 
and activity. Nevertheless, the results of the present study are not inconsistent with 
previous studies, considering the following points. First, Gli1 is a direct transcriptional 
target of GLI2.(47,48) Second,  GANT61, a pharmacological inhibitor used in the previous 
studies, inhibits both the GLI1 and GLI2 activities.(49,50) Accordingly, as explained by 
Faião-Flores et al.,(46) the increased expression of GLI2 by TGF-β through a non-
canonical Shh pathway results in an increase and decrease in GLI1 and MITF expression, 
respectively, which can be canceled by GANT61. Finally, although GLI1 and GLI2 have 
very similar consensus DNA-binding sites,(51) GLI2, but not GLI1, may specifically 
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regulate Mitf transcription along with GLI2-interacting cofactors, which have been 
proposed by Eichberger et al.(52) Taken together, it is conceivable that GLI1 and GLI2 
play distinct roles in the transcriptional regulation of Mitf. 
Recent studies have shown that a switch in the EMT-TF expression pattern from 
SNAIL2high/ZEB2high/TWIST1low/ZEB1low to SNAIL2low/ZEB2low/TWIST1high/ZEB1high 
occurs during melanoma progression.(24,25) Caramel et al.(24) further demonstrated that 
EMT-TF reprograming is associated with decreased MITF expression and activity. In 
addition, Richard et al.(53) reported that ZEB1 plays a key role as a major driver of 
melanoma cell plasticity and phenotypic resistance to BRAFi, and that Zeb1 KD increases 
the sensitivity to BRAFi in both MITFlow and MITFhigh cellular contexts. In this study, on 
the other hand, I found that Gli1 KD induced a mesenchymal-epithelial-like transition in 
melanoma cells, which was accompanied by severely decreased invasive and migratory 
properties, and by an increased expression of E-cadherin and downregulation of 
mesenchymal markers. I also observed decreased mRNA levels of Snail1, Zeb1, and 
Twist1, but not of Snail2 or Zeb2, in the Gli1 KD melanoma cells. It is reported that 
SNAIL1 and TWIST1 cooperatively control Zeb1 expression during EMT in epithelial 
cells.(54) Taken together with the results of my ChIP and Luc reporter assays (Figure 3.11), 
it is conceivable that GLI1 directly regulates the transcriptional expression of a subset of 
EMT-TFs, including Snail1 and Twist1, as in non-melanoma cancer cells,(55,56) to 
maintain the invasive activity of melanoma cells through MITF-independent mechanisms. 
Further studies are needed to clarify this issue. 
An increased expression of Gli1 has been observed in BRAFi-resistant melanoma 
cells and patient samples,(46) as well as during melanoma progression.(57) Taken together 
with my present results, GLI1 may play a role in generating a high level of intratumor 
heterogeneity in melanoma. Targeting GLI1 may therefore be an effective approach for 
melanoma therapy. Indeed, accumulating evidence suggests that GLI antagonists, of 
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which GANT61 has been most extensively studied in vitro and in animal models, are 
promising therapeutic candidates for a wide range of cancers, including melanoma.(58) 
Current therapy for metastatic melanoma using MEK inhibitor or BRAF inhibitor 
possess a great challenge. An alternative differentiation therapy by inducing MITF-
dependent melanocyte differentiation program has been proposed recently (59). However, 
since high or low expression of MITF may contribute to drug resistance mechanism, 
further understanding is required. Recently, several studies link the EMT and MITF-
dependent phenotype switching. However, ~14% of melanoma showed high expression 
of MITF and EMT marker and metastatic melanoma with high expression of MITF 
showed worse outcome as compared to the melanoma with low expression of MITF (60). 
These evidence together with my study suggest that in a certain condition, high MITF 
expression may coexist with EMT which give rise to melanoma subtype with high 
malignancy. Certainly, further understanding of this process might be helpful to design 
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